The potential therapeutic targets of bufalin included MDM2, PIK3CA, MAPK14, and MTOR, which can induce cell death through various mechanisms and exert anticancer properties against lung cancer, liver cancer, and other tumors [23, 24]. This evidence concerns the gene MAPK14 and lung cancer.